Clinical Trial Update: A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL) [Phase 2]

View source ↗

Summary

Phase 2 trial of A-dmDT390-bisFv(UCHT1) immunotoxin for cutaneous T-cell lymphoma (CTCL) has completed, with results from the study summarized.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Mycosis Fungoides
• Sezary Syndrome
• T-cell Leukemia
• T-cell Lymphoma

Drugs mentioned

• A-dmDT390-bisFv(UCHT1) immunotoxin

Snippet

Sponsor: Angimmune LLC | Conditions: T-cell Lymphomas, T-cell Leukemia | Phase 2 | Status: COMPLETED